(SNY) Sanofi ADR - Ratings and Ratios
Exchange: NASDAQ • Country: France • Currency: USD • Type: Common Stock • ISIN: US80105N1054
SNY: Vaccines, Medicines, Skincare, Diabetes, Oncology, Cardiovascular
Sanofi ADR (NASDAQ: SNY) stands as a global leader in healthcare, with a diverse portfolio that spans pharmaceuticals, vaccines, and consumer healthcare. This French multinational, headquartered in Paris, operates across the U.S., Europe, Canada, and internationally, offering a broad range of therapeutic solutions. Its strategic approach to innovation and collaboration positions it as a key player in addressing significant medical needs.
The Pharmaceuticals segment is a cornerstone of Sanofis business, featuring flagship products like DUPIXENT, which has revolutionized treatment in areas such as atopic dermatitis. Additionally, the company excels in neurology and immunology, with a robust pipeline targeting rare diseases, oncology, and blood disorders. Their diabetes and cardiovascular offerings further underscore their commitment to managing chronic conditions effectively.
Sanofis Vaccines segment is equally impressive, providing essential protection against diseases such as polio, pertussis, and influenza. Their extensive range includes travelers vaccines, highlighting their role in global health security and preventive care.
In the Consumer Healthcare space, Sanofi addresses everyday health needs with products for coughs, colds, allergies, and skincare. This segment not only diversifies their revenue streams but also ensures accessibility to essential health products for millions worldwide.
Strategic collaborations are pivotal to Sanofis innovation strategy. Partnerships with entities like Exscientia and Seagen Inc. underscore their commitment to cutting-edge research in oncology and immunology. These alliances not only enhance their R&D capabilities but also position them at the forefront of emerging therapies.
Financially, Sanofi ADR presents a compelling profile with a market cap of $136.24 billion, reflecting its stability and market presence. The forward P/E ratio of 12.80 suggests potential for future growth, making it an attractive consideration for investors seeking exposure to the pharmaceutical sector.
Category-wise, Sanofi ADR is listed on NASDAQ under the ticker SNY, classified under Pharmaceuticals within the broader healthcare industry. This classification aligns with its core competencies and market focus.
Additional Sources for SNY Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SNY Stock Overview
Market Cap in USD | 136,641m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2002-07-01 |
SNY Stock Ratings
Growth 5y | 36.7% |
Fundamental | 37.7% |
Dividend | 53.4% |
Rel. Strength Industry | 13.8 |
Analysts | 4.5/5 |
Fair Price Momentum | 52.43 USD |
Fair Price DCF | 54.25 USD |
SNY Dividends
Dividend Yield 12m | 3.78% |
Yield on Cost 5y | 4.66% |
Annual Growth 5y | 3.05% |
Payout Consistency | 97.2% |
SNY Growth Ratios
Growth Correlation 3m | 82.8% |
Growth Correlation 12m | 42.4% |
Growth Correlation 5y | 63.5% |
CAGR 5y | 4.28% |
CAGR/Mean DD 5y | 0.47 |
Sharpe Ratio 12m | 0.61 |
Alpha | 8.59 |
Beta | 0.20 |
Volatility | 21.60% |
Current Volume | 2081.5k |
Average Volume 20d | 2491.3k |
As of February 19, 2025, the stock is trading at USD 53.95 with a total of 2,081,505 shares traded.
Over the past week, the price has changed by +0.09%, over one month by +4.37%, over three months by +11.21% and over the past year by +15.15%.
Partly, yes. Based on ValueRay Fundamental Analyses, Sanofi ADR (NASDAQ:SNY) is currently (February 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 37.66 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SNY as of February 2025 is 52.43. This means that SNY is currently overvalued and has a potential downside of -2.82%.
Sanofi ADR has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy SNY.
- Strong Buy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, SNY Sanofi ADR will be worth about 57.9 in February 2026. The stock is currently trading at 53.95. This means that the stock has a potential upside of +7.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 63.5 | 17.7% |
Analysts Target Price | 63.1 | 16.9% |
ValueRay Target Price | 57.9 | 7.2% |